Kenneth Bloom
Head of Pathology Nucleai
Seminars
Thursday 25th September 2025
Novel ADC Insights to Inform Your Biomarker & CDx Strategy
11:00 am
- New research on how an antibody-drug conjugate (ADC) can bypass internalization, leading to the bystander effect
- How the tumor microenvironment and immune interactions could influence patient stratification and ADC-immunotherapy combo strategies
- How AI spatial proteomics and IHC, H&E-based quantitative biomarker scoring can give deeper insights into the MOA and efficacy of ADCs
